|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01093 CSPC PHARMA
Nominal 
4.800 0.000 (0.000%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 31,450,109 | 1.659% | 30,936,904 | 27,866,870 | 24,942,204 | 22,103,192 |
| Cost of Sales | (9,273,423) | 6.831% | (8,680,490) | (6,731,776) | (6,256,882) | (6,192,211) |
| Gross Profit | 22,176,686 | -0.358% | 22,256,414 | 21,135,094 | 18,685,322 | 15,910,981 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | 32,861 | -31.632% | 48,065 | 37,365 | 333,055 | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (54,196) | 252.036% | (15,395) | 22,443 | 13,532 | 58,407 | |
| Profit / (Loss) before Taxation | 7,389,372 | -2.544% | 7,582,261 | 6,847,096 | 6,391,023 | 4,626,162 | |
| Taxation | (1,316,679) | -2.483% | (1,350,211) | (1,158,972) | (1,162,013) | (892,810) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (199,368) | 41.738% | (140,660) | (82,939) | (69,355) | (19,246) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 5,873,325 | -3.580% | 6,091,390 | 5,605,185 | 5,159,655 | 3,714,106 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (233,985) | 7.512% | (217,637) | (175,576) | (90,588) | (32,314) |
| Depreciation & Amortisation | 1,117,490 | 6.637% | 1,047,939 | 865,471 | 808,807 | 691,595 |
| Directors' Emoluments | 84,048 | 14.121% | 73,648 | 54,944 | 49,952 | 49,097 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 49.470 | -3.209% | 51.110 | 46.890 | 43.160 | 31.070 |
| DPS (cts) | 25.399 | -- | 18.386 | 14.959 | 10.678 | 9.464 |
| Dividend Payout Ratio (%) | 51.342% | -- | 35.973% | 31.902% | 24.741% | 30.461% |
| Cash flow per share ($) | 0.352 | -- | 0.640 | 0.388 | 0.564 | 0.317 |
| NBV per share ($) | 2.789 | -- | 2.531 | 2.175 | 1.865 | 1.542 |
| Remarks: | Real time quote last updated: 24/12/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,020,374 |
| %Change | 1.799% |
| EPS / (LPS) | RMB 0.255 |
| NBV Per Share (¥) | RMB 2.930 |